Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents

Patent metadata

Field	Value
Publication number	US-11053236-B2
Application number	US-201716312024-A
Country	US
Kind code	B2
Filing date	Jun 21, 2017
Priority date	Jun 21, 2016
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

Compounds, compositions, and methods for the treatment of infections, inflammation, cancers, tinnitus, Meniere's disease, hearing loss, or bipolar disorder, or for providing cytoprotection against Clostridium difficile toxins, are disclosed.

First claim

What is claimed is:

1. A compound of Formula III:

wherein R is a C 1 -C 8 alkenyl, quinoline; furan; thiophene; tetrahydropyran; or, a Y-substituted Ph group;
wherein Y is N 3 , 1,2,3-triazole, C 1 -C 8 acyloxy, amino, C 1 -C 8 alkoxy Ph, vinyl, CO 2 H, or CO 2 R 6 ;
and,
wherein R 6 is furan, thiophene, Ph, or a C 1 -C 8 alkyl optionally substituted with one or more of the following: F, Cl, hydroxy, C 1 -C 8 alkoxy, C 1 -C 8 acyloxy, amino, C 1 -C 8 alkylamino, C 1 -C 8 dialkylamino, O—CH 2 -Ph, Ph, or vinyl.

2. The compound of claim 1 , having a structure of 506a, 506c, 506i-506j, or 506q-506u:

Assignees

• Univ Toledo

Inventors

• Sucheck Steven
• Thanna Sandeep
• Ronning Donald
• Landgraf Alexander

Classifications

• A61P27/16

  Otologicals · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D421/04 Primary

  directly linked by a ring-member-to-ring-member bond · CPC title

• A61P31/06

  for tuberculosis · CPC title